Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

170 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
MHC-binding peptides as immunotherapeutics for cancer.
Kobayashi H, Kennedy R, Lu J, Davila E, Celis E. Kobayashi H, et al. Immunol Invest. 2000 May;29(2):105-10. doi: 10.3109/08820130009062291. Immunol Invest. 2000. PMID: 10854176 No abstract available.
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E, Kennedy R, Celis E. Davila E, et al. Cancer Res. 2003 Jun 15;63(12):3281-8. Cancer Res. 2003. PMID: 12810660
Interestingly, whereas this combination therapy was effective when administered to tumor-bearing mice (therapeutic protocol), it had no significant effect when applied in the prophylactic mode (i.e., before the tumor challenge). ...
Interestingly, whereas this combination therapy was effective when administered to tumor-bearing mice (therapeutic protocol), it had no sign …
Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E, Celis E. Davila E, et al. J Immunol. 2000 Jul 1;165(1):539-47. doi: 10.4049/jimmunol.165.1.539. J Immunol. 2000. PMID: 10861094
However, peptide-based vaccines, in general, fail to elicit sufficiently strong CTL responses capable of producing therapeutic anti-tumor effects (i.e., prolongation of survival, tumor reduction). ...
However, peptide-based vaccines, in general, fail to elicit sufficiently strong CTL responses capable of producing therapeutic anti-tumor ef …
Biology of T lymphocytes.
Vallejo AN, Davila E, Weyand CM, Goronzy JJ. Vallejo AN, et al. Rheum Dis Clin North Am. 2004 Feb;30(1):135-57. doi: 10.1016/S0889-857X(03)00114-5. Rheum Dis Clin North Am. 2004. PMID: 15061572 Review.
TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements.
Zheng L, Asprodites N, Keene AH, Rodriguez P, Brown KD, Davila E. Zheng L, et al. Blood. 2008 Mar 1;111(5):2704-13. doi: 10.1182/blood-2007-07-104141. Epub 2007 Dec 17. Blood. 2008. PMID: 18086870 Free PMC article.
A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity.
So EC, Sallin MA, Zhang X, Chan SL, Sahni L, Schulze DH, Davila E, Strome SE, Jain A. So EC, et al. J Immunol Methods. 2013 Aug 30;394(1-2):40-8. doi: 10.1016/j.jim.2013.05.001. Epub 2013 May 13. J Immunol Methods. 2013. PMID: 23680234
TLR agonists: our best frenemy in cancer immunotherapy.
Kaczanowska S, Joseph AM, Davila E. Kaczanowska S, et al. J Leukoc Biol. 2013 Jun;93(6):847-63. doi: 10.1189/jlb.1012501. Epub 2013 Mar 8. J Leukoc Biol. 2013. PMID: 23475577 Free PMC article. Review.
Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR. Kapoor S, et al. Clin Cancer Res. 2018 Jan 1;24(1):234-247. doi: 10.1158/1078-0432.CCR-17-1629. Epub 2017 Oct 26. Clin Cancer Res. 2018. PMID: 29074603 Free PMC article.
170 results
Jump to page
Feedback